We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Research Letter |

Dermoscopic Evaluation of Melanocytic Nevi Changes With Combined Mitogen-Activated Protein Kinase Pathway Inhibitors Therapy for Melanoma ONLINE FIRST

Marie Perier-Muzet, MD1; Amélie Boespflug, MD1; Nicolas Poulalhon, MD2; Julie Caramel, PhD1; Anne-Laure Breton, MD2; Luc Thomas, MD, PhD2; Stephane Dalle, MD, PhD2
[+] Author Affiliations
1Cancer Research Center of Lyon, Lyon, France
2Department of Dermatology, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Lyon, France
JAMA Dermatol. Published online July 27, 2016. doi:10.1001/jamadermatol.2016.2426
Text Size: A A A
Published online


This observational study investigates nevi changes after combined BRAF inhibitor and mitogen-activated protein kinase pathway inhibitor therapy in patients with metastatic melanoma.

Previous studies1,2 have described the changes that occur in nevi and the induction of new melanomas during treatment with the BRAF inhibitor (BRAFi) vemurafenib in a cohort of patients with metastatic melanoma. These findings were later confirmed by others3 for the second approved BRAFi, dabrafenib mesylate. These changes are not completely understood but are probably due to the paradoxical activation of the mitogen-activated protein kinase (MAPK) signaling pathway in NRAS-mutated or wild-type BRAF melanocytes, notably via the heterodimerization of BRAF and CRAF, as demonstrated by proximity ligation assay on de novo melanomas in patients receiving BRAFi.4 Since then, mitogen-activated kinase kinase (MEK) inhibitors (MEKi) have been routinely administered in combination with BRAFi, owing to the improvement of progression-free survival rates compared with BRAFi alone. As expected with their mechanism of onset through the RAS-MEK pathway, the incidence of induced cutaneous squamous cell carcinomas was shown to be significantly lower with the combined treatment, whereas nevi changes have so far only been reported in isolated case-reports.5,6 We conducted an observational study of digital dermoscopy follow-up in a small cohort of patients treated with combination BRAFi and MEKi therapy to more precisely describe early dermoscopic modifications occurring to the nevi.

Figures in this Article

First Page Preview

View Large
First page PDF preview


Place holder to copy figure label and caption
Figure 1.
Dermoscopic Modifications Arising in Nevi During the Treatment Course

Patients received a combination of a BRAF inhibitor (BRAFi) and mitogen-activated kinase kinase inhibitor (MEKi). A, Evolution of the various dermoscopic criteria over the time with combined BRAFi-MEKi therapy. B, A comparison of the evolution of global pigmentation (main modified criterion) in patients receiving combination therapy with previously described global pigmentation during vemurafenib as monotherapy.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Evolution of 3 Melanocytic Lesions in 3 Patients

A, Changes in lesion 37 from patient 4 show global hypopigmentation after 6 months of combined BRAF inhibitor (BRAFi) and mitogen-activated kinase kinase inhibitor (MEKi) therapy. B, Dermoscopic changes in lesion number 12 from patient 7, after 3 months of combination therapy. C, Hyperpigmented changes in lesion 27 from patient 13 after cessation of cobimetinib fumarate therapy and 3 months of BRAFi monotherapy (dabrafenib mesylate), leading to a surgical excision (a 0.22-mm superficial spreading melanoma was diagnosed).

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles